Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Reviva Pharmaceuticals Holdings's EV-to-OCF or its related term are showing as below:
RVPH'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.75 Med: 0 Max: 0.76
Current: 0.75
During the past 7 years, the highest EV-to-OCF of Reviva Pharmaceuticals Holdings was 0.76. The lowest was 0.75. And the median was .
RVPH's EV-to-OCF is ranked worse than 77.06% of 1408
companies
in the Biotechnology industry
Industry Median: -3.715
vs RVPH: 0.75
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Reviva Pharmaceuticals Holdings's PE Ratio (TTM) for today is calculated as:
Reviva Pharmaceuticals Holdings's share price for today is $0.5185.
Reviva Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.423.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Reviva Pharmaceuticals Holdings EV-to-OCF Related Terms
Reviva Pharmaceuticals Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reviva Pharmaceuticals Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Reviva Pharmaceuticals Holdings's EV-to-OCF falls into.
Reviva Pharmaceuticals Holdings's current Enterprise Value is $-12.95 Mil.
Reviva Pharmaceuticals Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reviva Pharmaceuticals Holdings (RVPH) has a EV-to-OCF of 0.75 as of Aug. 28, 2026. Over the past decade, Reviva Pharmaceuticals Holdings' EV-to-OCF has ranged from 0.75 to 0.76. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #1085 out of 1408 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Reviva Pharmaceuticals Holdings' EV-to-OCF too high?
Reviva Pharmaceuticals Holdings' current EV-to-OCF is 0.75. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 0.76. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #1085 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' EV-to-OCF compare to CVKD and ACXP?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #1085 out of 1408 companies for EV-to-OCF. This places Reviva Pharmaceuticals Holdings in the lower half of its industry. Historically, Reviva Pharmaceuticals Holdings' own EV-to-OCF has ranged from 0.75 to 0.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Reviva Pharmaceuticals Holdings's current EV-to-OCF is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current EV-to-OCF of 0.75. The current EV-to-OCF is 0.75. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current EV-to-OCF is 0.75 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score
Get the complete analysis for RVPH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVPH has been successfully added to your 
